Shandong Boan Biotechnology Co. Ltd. reported revenue of RMB393.4 million for the six months ended 30 June 2025, compared to RMB362.9 million for the same period in 2024, an increase of RMB30.5 million or 8.4%. The company attributed the rise primarily to a 15.9% growth in sales of Boyounuo, Boyoubei, and Boluojia, which reached RMB385.3 million. Net profit for the period was RMB20.5 million. This marks the company's third consecutive reporting period with a positive profit contribution. The cost of sales for the period was RMB110.8 million, representing 28.2% of total revenue, compared to 22.1% for the same period in 2024. The increase in cost ratio was mainly due to a decrease in high-margin licensing revenue. Looking ahead, Shandong Boan Biotechnology expects continued growth in revenue and profit with the planned launch of more than three new products in the next two years. The company stated it is enhancing its development potential and market competitiveness through ongoing innovation and scientific management, and is advancing digital transformation initiatives by integrating digital analysis, automation, and AI technologies.